Literature DB >> 30570141

New tools for pathology: a user's review of a highly multiplexed method for in situ analysis of protein and RNA expression in tissue.

Jérémie Decalf1, Matthew L Albert1, James Ziai2.   

Abstract

Tumor cell heterogeneity and tumor cell-stromal interactions are being explored as determinants of disease progression and treatment resistance in solid tumor and hematological malignancies. As such, tools simultaneously capable of highly multiplexed profiling of tissues' protein and RNA content, as well as interrogation of rare or single cells, are required to precisely characterize constituent tumor cell populations, infiltrating lymphocytes and stromal elements. Access to spatial relationships will enable more precise characterization of tumors, support patient stratification and may help to identify novel drug targets. Multiple platforms are being developed to address these critical unmet needs. The NanoString digital spatial profiling (DSP) platform enables highly multiplexed, spatial assessment of protein and/or RNA targets in tissues by detecting oligonucleotide barcodes conjugated via a photocleavable linker to primary antibodies or nucleic acid probes. Although this platform enables high-dimensional spatial interrogation of tissue protein and RNA expression, a detailed understanding of its composition, function and chemistry is advisable to guide experimental design and data interpretation. The purpose of this review is to provide an independent, comprehensive description of the DSP technology, including an overview of NanoString's capture and antibody barcode conjugation chemistries, experimental workflow, data output and analysis methods. The DSP technology will be discussed in the context of other highly multiplexed immunohistochemistry methods, including imaging mass cytometry and multiplexed ion beam imaging, to inform potential users of the advantages and limitations of each. Additional issues such as preanalytical variability, sampling and specimen adequacy will be considered with respect to the platforms to inform potential experimental design.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  NanoString; in situ hybridization; multiplexed immunohistochemistry; tissue biomarkers; tumor microenvironment

Year:  2019        PMID: 30570141     DOI: 10.1002/path.5223

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  35 in total

1.  SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors:  Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 2.  Characterizing the ecological and evolutionary dynamics of cancer.

Authors:  Nastaran Zahir; Ruping Sun; Daniel Gallahan; Robert A Gatenby; Christina Curtis
Journal:  Nat Genet       Date:  2020-07-27       Impact factor: 38.330

3.  Immune escape mechanisms for TCRLBCL.

Authors:  Wing C Chan
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

Review 4.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

5.  NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.

Authors:  Sandra M Swain; Gong Tang; Heather Ann Brauer; David S Goerlitz; Peter C Lucas; André Robidoux; Brent T Harris; Hanna Bandos; Yuqi Ren; Charles E Geyer; Priya Rastogi; Eleftherios P Mamounas; Norman Wolmark
Journal:  Clin Cancer Res       Date:  2020-05-05       Impact factor: 12.531

6.  TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response.

Authors:  Nathan P McMahon; Allison Solanki; Lei G Wang; Antonio R Montaño; Jocelyn A Jones; Kimberley S Samkoe; Kenneth M Tichauer; Summer L Gibbs
Journal:  Mol Imaging Biol       Date:  2021-03-09       Impact factor: 3.488

Review 7.  Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy.

Authors:  Satyen H Gohil; J Bryan Iorgulescu; David A Braun; Derin B Keskin; Kenneth J Livak
Journal:  Nat Rev Clin Oncol       Date:  2020-12-04       Impact factor: 66.675

8.  Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness.

Authors:  Junya Ning; Yingnan Ye; Dechao Bu; Gang Zhao; Tianqiang Song; Pengpeng Liu; Wenwen Yu; Hailong Wang; Hui Li; Xiubao Ren; Guoguang Ying; Yi Zhao; Jinpu Yu
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

Review 9.  Controversies around epithelial-mesenchymal plasticity in cancer metastasis.

Authors:  Elizabeth D Williams; Dingcheng Gao; Andrew Redfern; Erik W Thompson
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

10.  An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Authors:  Paula Voabil; Marjolein de Bruijn; Lisanne M Roelofsen; Sanne H Hendriks; Simone Brokamp; Marlous van den Braber; Annegien Broeks; Joyce Sanders; Petra Herzig; Alfred Zippelius; Christian U Blank; Koen J Hartemink; Kim Monkhorst; John B A G Haanen; Ton N Schumacher; Daniela S Thommen
Journal:  Nat Med       Date:  2021-07-08       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.